Lang ø mand Sebastien Beauzile bliver første nye yorker helbredt af seglcellesygdom med lysgenia genbehandling

Sebastien Beauzile spent most of his childhood measuring time in hospital beds. The 21-year-old from Laurelton, Queens, who grew up on Long Island, lived with sickle cell disease so severe that pain crises could lock his joints and send him back through the same emergency-room doors week after week. On December 17, 2024, doctors at Cohen Children’s Medical Center infused him with Lyfgenia, a one-time gene therapy that rewrites how his bone marrow makes hemoglobin. By March 13, 2025, his hematologist was willing to say the words patients with this disease almost never hear: the sickle cell disease is gone.

"Jeg har ikke ondt mere", Beauzile fortalte journalister på pressekonferencen Northwell Health iscenesat at markere, hvad han kalder sin "re-fødselsdag". Personalet sang "Tillykke med fødselsdagen". Han svarede med en linje, der nu følger ham rundt på internettet: "Jeg er ustoppelig".

AEGIS Alliance følger hans sag, fordi det ikke kun er en medicinsk først for New York. Det er en test af, om en $3,1 millioner terapi kan forlade pressekonferencen og nå de 100.000 mennesker i USA, der stadig lever med den samme mutation.

Hvad seglcelle gør ved en krop

Sickle cell disease is a genetic error in hemoglobin, the protein that lets red blood cells carry oxygen. Instead of sliding through vessels as flexible discs, the cells collapse into rigid crescents. Those crescents jam small arteries. The result is vaso-occlusive pain, stroke risk, organ damage, and a shortened life. In the United States the condition hits Black families hardest. About 1 in 365 Black or African American babies is born with it.

I årtier stoppede værktøjskassen ved smertestillende medicin, transfusioner og hydroxyurea. En matchende knoglemarvstransplantation kunne kurere et par heldige. De fleste patienter fandt aldrig en donor. Beauziles liv fulgte det fælles manuskript. "Jeg var dybest set ind og ud af hospitalet", Han sagde:"Jeg tror, jeg tilbragte mere tid på hospitalet, end jeg gjorde derhjemme". Under en krise blev bevægelsen selv fjenden. "Du kan ikke gå. Du kan ikke bevæge dig. Du kan ikke gøre noget".

Hvordan Lyfgenia faktisk virker

Lyfgenia, sold as lovotibeglogene autotemcel by bluebird bio, does not edit the broken gene the way CRISPR does. Technicians harvest the patient’s own hematopoietic stem cells, then use a disabled lentivirus to insert a working copy of a hemoglobin gene. That insert tells the cells to manufacture HbAT87Q, a hemoglobin designed to resist sickling. The patient then receives busulfan chemotherapy to empty the bone marrow. The modified cells go back in through an intravenous line and, if the graft takes, start producing blood that no longer collapses.

The U.S. Food and Drug Administration approved Lyfgenia in December 2023 for patients 12 and older with a history of vaso-occlusive events. The same month it approved Casgevy, the CRISPR-based rival from Vertex and CRISPR Therapeutics. Lyfgenia carries a boxed warning. Two people treated with an earlier version of the platform later developed acute myeloid leukemia. Recipients are told to stay in lifelong cancer surveillance.

Cohen Children er blevet det første hospital i New York State til at administrere det kommercielle produkt. Dr. Banu Aygun, Beauziles hæmatolog, fortalte lokale forretninger omskrivning af hans marv havde holdt. CBS New York har rapporteret, at han har været fri for kriser siden infusionen i december.

Prisen på en engangskur

A list price of about $3.1 million is not a rounding error for a Medicaid program. Casgevy lists near $2.2 million. Both therapies demand specialized centers, weeks of isolation, and fertility counseling because busulfan can sterilize a patient. Those barriers showed up in the sales reports. Roughly two years after approval, only a few dozen people with sickle cell disease had received an infusion of either product. Bluebird was taken private after struggling to sell its gene therapies. Vertex reported modest early Casgevy revenue and a pipeline of patients whose cells had been collected but not yet infused.

Federal officials tried to pry the door open. The Centers for Medicare and Medicaid Services launched a Cell and Gene Therapy Access Model that ties payment to outcomes and lets states buy the drugs through a coordinated deal. By mid-2025, 33 states plus the District of Columbia and Puerto Rico had signed on, covering about 84 percent of Medicaid beneficiaries with sickle cell disease. New York is also pouring capital into the manufacturing side. Governor Kathy Hochul and Northwell Health announced a cell and gene therapy campus in Lake Success, now branded New York Biogenesis Park, with a first-phase tower planned on Northwell’s campus and state money of up to $150 million behind a larger buildout targeted for the end of the decade.

En første i New York, ikke en første på Jorden

Beauzile is New York’s first commercial Lyfgenia success, not the first person ever treated this way. In January 2024, 12-year-old Kendric Cromer of the Washington suburbs became the first person in the world to start a commercially approved sickle cell gene therapy after the FDA green light. Victoria Gray, treated in a CRISPR trial in 2019, had already shown that editing fetal hemoglobin genes could shut the disease down. An 8-year-old in New York separately became the state’s first patient to receive an FDA-approved gene therapy for beta-thalassemia, a cousin blood disorder. The science is no longer theoretical. The bottleneck is capacity, money, and the willingness of hospitals to stand up the apheresis and transplant infrastructure.

New York Blood Center staff who ran Beauzile’s three collection sessions have described the work as a quiet piece of the milestone. Advocacy groups have tried to keep the disease visible. NewYork-Presbyterian’s Dalio Center for Health Justice launched an #IBall4SickleCell campaign around a special-edition basketball, a reminder that a condition this common in Black communities still fights for attention and research dollars.

Hvad ustoppelig faktisk betyder

Beauziles nye liv er bygget ud fra almindelige sætninger. Han kan vandre. Han kan svømme. Han kan stå i kold luft uden at antage, at vejret vil sætte ham tilbage på en afdeling. "Jeg behøver ikke at bekymre mig om at blive syg fra kulden", Han sagde:"Jeg har været ude i kulden, og jeg har haft det fint". Rejse, når en beregning af, om en krise ville ramme langt fra hans læger, er nu på bordet.

Den menneskelige skala er det punkt, AEGIS Alliancen hele tiden vender tilbage til. En genterapi, der virker i et Long Island infusionsrum er en historie. Et system, der kan gentage det for titusinder af mennesker, er en politisk kamp. Lignende medicinske spring, fra en titanium hjerte, der gik en australsk patient ud af hospitalet til a svampemolekyle syntetiseret efter 50 år for barndom hjernetumorer, løber ind i samme væg: bevis i en enkelt krop ikke automatisk bliver adgang.

Den ufærdige del af historien

Doctors will watch Beauzile for malignancy for the rest of his life. Insurers will watch the invoice. States in the CMS model will watch whether the outcomes they paid for actually appear. Other New Yorkers with sickle cell disease are already in workups at the same Northwell program. Some will be offered Casgevy instead. Some will be told their organs are too damaged, or that they cannot tolerate the chemotherapy step.

For one 21-year-old, the argument is already over. The blockade he described is behind him. Whether the rest of the country gets the same chance depends on factories in Lake Success, Medicaid contracts in 33 statehouses, and a health system that has historically underfunded the people this mutation hits first. Beauzile’s re-birthday is real. The waiting list behind him is real too.